Implications of Microscopic Satellites of the Primary and Extracapsular Lymph Node Spread in Patients With High-Risk Melanoma: Pathologic Corollary of Eastern Cooperative Oncology Group Trial E1690

PURPOSE: To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFNα)-2b. PATIENTS AND METHODS: E1690 included 642...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 20; no. 8; pp. 2053 - 2057
Main Authors Rao, U.N.M., Ibrahim, J., Flaherty, L.E., Richards, J., Kirkwood, J.M.
Format Journal Article
LanguageEnglish
Published Baltimore, MD American Society of Clinical Oncology 15.04.2002
Lippincott Williams & Wilkins
Subjects
Online AccessGet full text
ISSN0732-183X
1527-7755
DOI10.1200/JCO.2002.08.024

Cover

Abstract PURPOSE: To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFNα)-2b. PATIENTS AND METHODS: E1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma. Patients were randomized into high- and low-dose rIFNα-2b treatment arms and an observation arm. Pathologic slides were reviewed for selected parameters from at least half of the subjects in all three arms. Evaluation of the primary tumor included notations regarding ulceration, mitotic activity, thickness, microscopic satellites (MS), and nodal ECS on a standardized pathology form. These data were collated in relation to relapse-free survival (RFS) and overall survival (OS) at 50 months’ follow-up and studied using Cox regression analysis. RESULTS: Ulceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms. The presence of MS was correlated with RFS (P = .0008) and OS (P = .05). ECS correlated with RFS (hazard ratio = 1.44, P = .032) but not OS (P = .11). CONCLUSION: The presence of MS (in 6% [18 of 308 patients]) had a significant adverse impact on both RFS (P = .0008) and OS (P = .053). Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis). The presence of ECS in lymph nodes had a significant adverse effect on RFS (P = .032) but not on OS.
AbstractList To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFN alpha)-2b.PURPOSETo correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFN alpha)-2b.E1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma. Patients were randomized into high- and low-dose rIFN alpha-2b treatment arms and an observation arm. Pathologic slides were reviewed for selected parameters from at least half of the subjects in all three arms. Evaluation of the primary tumor included notations regarding ulceration, mitotic activity, thickness, microscopic satellites (MS), and nodal ECS on a standardized pathology form. These data were collated in relation to relapse-free survival (RFS) and overall survival (OS) at 50 months' follow-up and studied using Cox regression analysis.PATIENTS AND METHODSE1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma. Patients were randomized into high- and low-dose rIFN alpha-2b treatment arms and an observation arm. Pathologic slides were reviewed for selected parameters from at least half of the subjects in all three arms. Evaluation of the primary tumor included notations regarding ulceration, mitotic activity, thickness, microscopic satellites (MS), and nodal ECS on a standardized pathology form. These data were collated in relation to relapse-free survival (RFS) and overall survival (OS) at 50 months' follow-up and studied using Cox regression analysis.Ulceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms. The presence of MS was correlated with RFS (P =.0008) and OS (P =.05). ECS correlated with RFS (hazard ratio = 1.44, P =.032) but not OS (P =.11).RESULTSUlceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms. The presence of MS was correlated with RFS (P =.0008) and OS (P =.05). ECS correlated with RFS (hazard ratio = 1.44, P =.032) but not OS (P =.11).The presence of MS (in 6% [18 of 308 patients]) had a significant adverse impact on both RFS (P =.0008) and OS (P =.053). Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis). The presence of ECS in lymph nodes had a significant adverse effect on RFS (P =.032) but not on OS.CONCLUSIONThe presence of MS (in 6% [18 of 308 patients]) had a significant adverse impact on both RFS (P =.0008) and OS (P =.053). Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis). The presence of ECS in lymph nodes had a significant adverse effect on RFS (P =.032) but not on OS.
To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFN alpha)-2b. E1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma. Patients were randomized into high- and low-dose rIFN alpha-2b treatment arms and an observation arm. Pathologic slides were reviewed for selected parameters from at least half of the subjects in all three arms. Evaluation of the primary tumor included notations regarding ulceration, mitotic activity, thickness, microscopic satellites (MS), and nodal ECS on a standardized pathology form. These data were collated in relation to relapse-free survival (RFS) and overall survival (OS) at 50 months' follow-up and studied using Cox regression analysis. Ulceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms. The presence of MS was correlated with RFS (P =.0008) and OS (P =.05). ECS correlated with RFS (hazard ratio = 1.44, P =.032) but not OS (P =.11). The presence of MS (in 6% [18 of 308 patients]) had a significant adverse impact on both RFS (P =.0008) and OS (P =.053). Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis). The presence of ECS in lymph nodes had a significant adverse effect on RFS (P =.032) but not on OS.
PURPOSE: To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the intergroup study E1690 in relation to the impact of recombinant interferon-alfa (rIFNα)-2b. PATIENTS AND METHODS: E1690 included 642 patients with American Joint Committee on Cancer stage IIB or III cutaneous melanoma. Patients were randomized into high- and low-dose rIFNα-2b treatment arms and an observation arm. Pathologic slides were reviewed for selected parameters from at least half of the subjects in all three arms. Evaluation of the primary tumor included notations regarding ulceration, mitotic activity, thickness, microscopic satellites (MS), and nodal ECS on a standardized pathology form. These data were collated in relation to relapse-free survival (RFS) and overall survival (OS) at 50 months’ follow-up and studied using Cox regression analysis. RESULTS: Ulceration, mitotic activity, thickness, and size of tumor-bearing lymph nodes did not show a statistically significant correlation with either OS or RFS across all treatment arms. The presence of MS was correlated with RFS (P = .0008) and OS (P = .05). ECS correlated with RFS (hazard ratio = 1.44, P = .032) but not OS (P = .11). CONCLUSION: The presence of MS (in 6% [18 of 308 patients]) had a significant adverse impact on both RFS (P = .0008) and OS (P = .053). Ulceration, mitotic activity, thickness, and number of positive lymph nodes had no significant effect on OS in this subset study (univariate or multivariate Cox analysis). The presence of ECS in lymph nodes had a significant adverse effect on RFS (P = .032) but not on OS.
Author J. Richards
J. Ibrahim
L.E. Flaherty
U.N.M. Rao
J.M. Kirkwood
Author_xml – sequence: 1
  givenname: U.N.M.
  surname: Rao
  fullname: Rao, U.N.M.
  organization: From the Departments of Pathology and Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Melanoma Center, University of Pittsburgh Cancer Institute Pittsburgh, PA; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA; Wayne State University, Harper-Grace Hospitals, Detroit, MI; and University of Chicago Medical Center, Chicago, IL
– sequence: 2
  givenname: J.
  surname: Ibrahim
  fullname: Ibrahim, J.
  organization: From the Departments of Pathology and Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Melanoma Center, University of Pittsburgh Cancer Institute Pittsburgh, PA; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA; Wayne State University, Harper-Grace Hospitals, Detroit, MI; and University of Chicago Medical Center, Chicago, IL
– sequence: 3
  givenname: L.E.
  surname: Flaherty
  fullname: Flaherty, L.E.
  organization: From the Departments of Pathology and Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Melanoma Center, University of Pittsburgh Cancer Institute Pittsburgh, PA; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA; Wayne State University, Harper-Grace Hospitals, Detroit, MI; and University of Chicago Medical Center, Chicago, IL
– sequence: 4
  givenname: J.
  surname: Richards
  fullname: Richards, J.
  organization: From the Departments of Pathology and Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Melanoma Center, University of Pittsburgh Cancer Institute Pittsburgh, PA; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA; Wayne State University, Harper-Grace Hospitals, Detroit, MI; and University of Chicago Medical Center, Chicago, IL
– sequence: 5
  givenname: J.M.
  surname: Kirkwood
  fullname: Kirkwood, J.M.
  organization: From the Departments of Pathology and Medicine, University of Pittsburgh School of Medicine, University of Pittsburgh Medical Center, Melanoma Center, University of Pittsburgh Cancer Institute Pittsburgh, PA; Department of Biostatistics, Dana-Farber Cancer Institute, Boston, MA; Wayne State University, Harper-Grace Hospitals, Detroit, MI; and University of Chicago Medical Center, Chicago, IL
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13636678$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/11956265$$D View this record in MEDLINE/PubMed
BookMark eNp1kk9v1DAQxSNURLeFMzfkC9yy9Z_Ecbih1dIWbdmKFsHNcpxJ4-LEwU6A_YB8L5zuAhISp5Hs37zRvHknyVHvekiS5wQvCcX47N1qu4yVLrFYYpo9ShYkp0VaFHl-lCxwwWhKBPt8nJyEcI8xyQTLnyTHhJQ5pzxfJD8vu8EarUbj-oBcg66M9i5oNxiNbtQI1poRHn7GFtC1N53yO6T6Gq1_jF5pNYTJKo82u25o0XtXA7oZPKgamR5dR13ox4A-mbFFF-auTT-Y8AVdgVW969TrmWiddXdx2sp5Z-2sHoetVRjB9_HRDeCjzDdA217P6A6dezcN6NYbZdGa8BI_TR43ygZ4dqinyce369vVRbrZnl-u3mxSzfJsTJu6xAoqEJQRIBhwTfKyqlhdCUXLWhCRiYZSjrnWJQfKmcjqRmteQp0VTcVOk1d73cG7rxOEUXYm6OiR6sFNQRaE4wyLLIIvDuBUdVDLYe-b_G18BF4eABW0so1XvTbhL8c447wQkcv33HyV4KGR2owP14rmGysJlnMQZAyCnIMgsZAxCLHv7J--P9L_7Tjs1sYzfTceZOiUtXEBKu-1o1iKyOeM_QJ5iMR_
CitedBy_id crossref_primary_10_1245_s10434_018_7006_4
crossref_primary_10_1016_j_jaad_2011_04_031
crossref_primary_10_1016_j_jaad_2022_10_027
crossref_primary_10_1038_s41379_020_0500_9
crossref_primary_10_1002_cncr_24627
crossref_primary_10_1016_S1578_2190_11_70800_9
crossref_primary_10_1016_j_jaad_2018_08_055
crossref_primary_10_3389_fcell_2023_1290696
crossref_primary_10_1111_j_1365_2559_2012_04279_x
crossref_primary_10_1245_s10434_013_3092_5
crossref_primary_10_1097_DSS_0000000000001643
crossref_primary_10_1016_j_ejso_2014_03_002
crossref_primary_10_1245_s10434_009_0353_4
crossref_primary_10_1016_j_ad_2011_01_001
crossref_primary_10_1016_j_cps_2009_07_001
crossref_primary_10_4065_82_4_490
crossref_primary_10_1002_cam4_1320
crossref_primary_10_1016_j_mcna_2021_04_005
crossref_primary_10_1200_JCO_2009_23_4799
crossref_primary_10_1080_17512433_2019_1689121
crossref_primary_10_1245_s10434_011_1986_7
crossref_primary_10_1093_jnci_djaa012
crossref_primary_10_3390_jcm10214994
crossref_primary_10_1007_s40291_018_0318_z
crossref_primary_10_1007_s00330_021_07852_7
crossref_primary_10_1016_j_det_2012_04_007
crossref_primary_10_5858_2003_127_e365_PQCAPL
crossref_primary_10_1080_14737140_2018_1489246
crossref_primary_10_1309_AJCPTXMEFOVYWDA6
crossref_primary_10_1016_j_ejso_2020_09_005
crossref_primary_10_1097_DAD_0000000000002817
crossref_primary_10_1016_j_pathol_2015_12_005
crossref_primary_10_1038_modpathol_3800517
crossref_primary_10_1016_j_coms_2021_12_001
crossref_primary_10_1016_j_ejca_2019_03_010
crossref_primary_10_3322_caac_21409
crossref_primary_10_1245_s10434_013_3388_5
crossref_primary_10_3390_cancers16050895
crossref_primary_10_1016_j_ctrv_2020_102032
crossref_primary_10_1590_S1677_5538_IBJU_2013_06_08
Cites_doi 10.1200/JCO.1995.13.9.2361
10.1002/(SICI)1097-0347(199710)19:7<589::AID-HED5>3.0.CO;2-3
10.1200/JCO.2001.19.16.3622
10.1002/1097-0142(20000715)89:2<453::AID-CNCR34>3.0.CO;2-V
10.1002/1097-0142(19851001)56:7<1597::AID-CNCR2820560722>3.0.CO;2-5
10.1016/0002-9610(86)90307-7
10.1288/00005537-199105000-00010
10.1002/jso.2930250404
10.1200/JCO.2000.18.12.2444
10.1097/00000658-199111000-00014
10.1097/00000658-199110000-00013
10.1001/archotol.1981.00790480001001
10.1111/j.1365-2273.1982.tb01581.x
10.1007/BF02071524
10.1001/archderm.134.8.983
10.1097/00005537-200009000-00017
10.1046/j.1365-2168.2000.01439.x
10.1001/archsurg.1991.01410360031006
10.1016/S0025-7125(05)70418-1
10.1177/000313480006600602
10.1002/(SICI)1097-0142(19990815)86:4<617::AID-CNCR10>3.0.CO;2-S
10.1002/1097-0142(19840515)53:10<2183::AID-CNCR2820531029>3.0.CO;2-9
10.1177/000348949910800710
10.1097/00000658-198107000-00019
10.1007/BF02303638
10.1080/028418699431113
10.1002/1097-0142(19950615)75:12<2885::AID-CNCR2820751215>3.0.CO;2-3
10.1016/S1072-7515(00)00313-6
10.1046/j.1365-2559.1998.00523.x
10.1007/s10434-000-0469-z
10.1200/JCO.2001.19.16.3635
10.1097/00000658-199008000-00002
10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D
10.1016/S0169-5002(97)00072-X
ContentType Journal Article
Copyright 2002 INIST-CNRS
Copyright_xml – notice: 2002 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1200/JCO.2002.08.024
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Pharmacy, Therapeutics, & Pharmacology
EISSN 1527-7755
EndPage 2057
ExternalDocumentID 11956265
13636678
10_1200_JCO_2002_08_024
jco20_8_2053
Genre Research Support, U.S. Gov't, P.H.S
Clinical Trial
Randomized Controlled Trial
Journal Article
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: CA39229
– fundername: NCI NIH HHS
  grantid: CA66636
– fundername: NCI NIH HHS
  grantid: CA14028
– fundername: NCI NIH HHS
  grantid: CA21115
– fundername: NCI NIH HHS
  grantid: CA32102
– fundername: NCI NIH HHS
  grantid: CA23318
GroupedDBID -
08R
0R
2WC
34G
39C
3O-
4.4
53G
55
5GY
5RE
8F7
8WZ
A6W
AARDX
AAWTL
AAYEP
ABFLS
ABOCM
ACGFS
ADBIT
AENEX
AFFNX
ALMA_UNASSIGNED_HOLDINGS
ASPBG
AVWKF
AWKKM
AZFZN
CS3
DIK
EBS
EJD
EX3
F5P
FD8
FEDTE
FH7
GJ
H13
HVGLF
HZ
IH2
KQ8
L7B
N9A
O9-
OK1
OVD
OWW
P2P
RHI
RUC
SJN
SV3
TWZ
UDS
VH1
WH7
WOQ
WOW
X7M
YCJ
ZA5
ZGI
---
.55
.GJ
08G
0R~
18M
AAKAS
AAYXX
ABBLC
ABJNI
ACGFO
ADZCM
AEGXH
AI.
AIAGR
C45
CITATION
F9R
FBNNL
HZ~
MJL
N4W
QTD
R1G
RLZ
TEORI
TR2
UHU
VVN
YFH
YQY
08P
29K
5VS
AAQOH
AAQQT
ACGUR
ADBBV
BAWUL
BYPQX
D-I
GX1
IPNFZ
IQODW
J5H
K-O
LSO
NTWIH
RIG
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ID FETCH-LOGICAL-c354t-fd90aebe8231e10e0d159bb3db8a29d81848f22606cc96e26384dfcc69ed47fb3
ISSN 0732-183X
IngestDate Fri Jul 11 09:45:27 EDT 2025
Sat Sep 28 07:48:04 EDT 2024
Mon Jul 21 09:14:40 EDT 2025
Tue Jul 01 02:23:47 EDT 2025
Thu Apr 24 22:55:30 EDT 2025
Tue Jan 05 20:17:23 EST 2021
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Antineoplastic agent
Human
Skin disease
Prognosis
Lymph node
Cytokine
Melanoma
Malignant lymphadenopathy
Malignant hemopathy
Malignant tumor
Metastasis
Regional
Extracapsular
Treatment
Interferon alpha 2b
Immunotherapy
Micrometastasis
Skin
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c354t-fd90aebe8231e10e0d159bb3db8a29d81848f22606cc96e26384dfcc69ed47fb3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
PMID 11956265
PQID 71604084
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_71604084
pubmed_primary_11956265
pascalfrancis_primary_13636678
crossref_citationtrail_10_1200_JCO_2002_08_024
crossref_primary_10_1200_JCO_2002_08_024
highwire_smallpub2_jco20_8_2053
ProviderPackageCode RHI
CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2002-04-15
PublicationDateYYYYMMDD 2002-04-15
PublicationDate_xml – month: 04
  year: 2002
  text: 2002-04-15
  day: 15
PublicationDecade 2000
PublicationPlace Baltimore, MD
PublicationPlace_xml – name: Baltimore, MD
– name: United States
PublicationTitle Journal of clinical oncology
PublicationTitleAlternate J Clin Oncol
PublicationYear 2002
Publisher American Society of Clinical Oncology
Lippincott Williams & Wilkins
Publisher_xml – name: American Society of Clinical Oncology
– name: Lippincott Williams & Wilkins
References R9-107008
R8-107008
R7-107008
R26-107008
R17-107008
R18-107008
R33-107008
R34-107008
R35-107008
R36-107008
R16-107008
R19-107008
R15-107008
R14-107008
R31-107008
R38-107008
R22-107008
R23-107008
R30-107008
R37-107008
R32-107008
R24-107008
R28-107008
R20-107008
R21-107008
R25-107008
R27-107008
R29-107008
R12-107008
R6-107008
R11-107008
R13-107008
R1-107008
R2-107008
R3-107008
R4-107008
R5-107008
R10-107008
References_xml – ident: R9-107008
  doi: 10.1200/JCO.1995.13.9.2361
– ident: R16-107008
  doi: 10.1002/(SICI)1097-0347(199710)19:7<589::AID-HED5>3.0.CO;2-3
– ident: R11-107008
  doi: 10.1200/JCO.2001.19.16.3622
– ident: R34-107008
  doi: 10.1002/1097-0142(20000715)89:2<453::AID-CNCR34>3.0.CO;2-V
– ident: R22-107008
  doi: 10.1002/1097-0142(19851001)56:7<1597::AID-CNCR2820560722>3.0.CO;2-5
– ident: R1-107008
  doi: 10.1016/0002-9610(86)90307-7
– ident: R38-107008
– ident: R20-107008
  doi: 10.1288/00005537-199105000-00010
– ident: R10-107008
  doi: 10.1002/jso.2930250404
– ident: R29-107008
  doi: 10.1200/JCO.2000.18.12.2444
– ident: R2-107008
  doi: 10.1097/00000658-199111000-00014
– ident: R5-107008
– ident: R8-107008
  doi: 10.1097/00000658-199110000-00013
– ident: R21-107008
  doi: 10.1001/archotol.1981.00790480001001
– ident: R18-107008
  doi: 10.1111/j.1365-2273.1982.tb01581.x
– ident: R3-107008
– ident: R17-107008
  doi: 10.1007/BF02071524
– ident: R30-107008
  doi: 10.1001/archderm.134.8.983
– ident: R33-107008
  doi: 10.1097/00005537-200009000-00017
– ident: R15-107008
  doi: 10.1046/j.1365-2168.2000.01439.x
– ident: R27-107008
  doi: 10.1001/archsurg.1991.01410360031006
– ident: R37-107008
  doi: 10.1016/S0025-7125(05)70418-1
– ident: R36-107008
  doi: 10.1177/000313480006600602
– ident: R6-107008
  doi: 10.1002/(SICI)1097-0142(19990815)86:4<617::AID-CNCR10>3.0.CO;2-S
– ident: R26-107008
  doi: 10.1002/1097-0142(19840515)53:10<2183::AID-CNCR2820531029>3.0.CO;2-9
– ident: R19-107008
  doi: 10.1177/000348949910800710
– ident: R28-107008
  doi: 10.1097/00000658-198107000-00019
– ident: R4-107008
  doi: 10.1007/BF02303638
– ident: R31-107008
  doi: 10.1080/028418699431113
– ident: R24-107008
  doi: 10.1002/1097-0142(19950615)75:12<2885::AID-CNCR2820751215>3.0.CO;2-3
– ident: R7-107008
  doi: 10.1016/S1072-7515(00)00313-6
– ident: R14-107008
  doi: 10.1002/jso.2930250404
– ident: R32-107008
  doi: 10.1046/j.1365-2559.1998.00523.x
– ident: R35-107008
  doi: 10.1007/s10434-000-0469-z
– ident: R12-107008
  doi: 10.1200/JCO.2001.19.16.3635
– ident: R13-107008
  doi: 10.1097/00000658-199008000-00002
– ident: R25-107008
  doi: 10.1002/(SICI)1097-0142(20000315)88:6<1484::AID-CNCR29>3.0.CO;2-D
– ident: R23-107008
  doi: 10.1016/S0169-5002(97)00072-X
SSID ssj0014835
Score 1.9064752
Snippet PURPOSE: To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome...
To correlate the presence of extracapsular spread (ECS) of regional nodal metastases, and micrometastasis near the primary tumor, with disease outcome in the...
SourceID proquest
pubmed
pascalfrancis
crossref
highwire
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2053
SubjectTerms Antineoplastic agents
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Humans
Immunotherapy
Interferon-alpha - therapeutic use
Lymphatic Metastasis
Medical sciences
Melanoma - drug therapy
Melanoma - pathology
Mitotic Index
Neoplasm Staging
Pharmacology. Drug treatments
Recombinant Proteins
Skin Neoplasms - drug therapy
Skin Neoplasms - pathology
Survival Analysis
Ulcer
Title Implications of Microscopic Satellites of the Primary and Extracapsular Lymph Node Spread in Patients With High-Risk Melanoma: Pathologic Corollary of Eastern Cooperative Oncology Group Trial E1690
URI http://jco.ascopubs.org/content/20/8/2053.abstract
https://www.ncbi.nlm.nih.gov/pubmed/11956265
https://www.proquest.com/docview/71604084
Volume 20
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3bbhMxELXaIiFeEJRbCxQ_oAop3WXrvYY3FKVqgTSlTUXfVl7bqwYlu1GTSoT_47-Ysb2XFCouL1G12YsbnzOeWc-cIeS1En6cdGXoCOkLJ8jz0OFg9gDLYaJy3BvSQtqD4-jwPPhwEV6srW-3spauF5krvv-2ruR_ZhWOwbxilew_zGx9UzgAf8P8wifMMHz-1RwftdPBMZcFs-uwzmQsOmdca20ujKgsupcnVlgCX5X3vy2uuOAQImMW6qclzGnnuJSqczYDLxL1mFC8f6zL377gq1rMB3FOMQ99oCa8KKe6pw-cY60nGJYrhJTZse9zrb8AB8uZstriw0IYvSfz_muk24X0cf_sFge5Ltos7ZUVOM7dY3fgdk55Wef_uJ0jCPsvx9M6wcjtu52DCb9E7eDWaVZIYPVtB8ONG1Pv2SowQMtnc1oxZ6UazbA9GmNCY585YLQuzGpnTTyLIaYw4sDVGsC8FtaTtkH3jJbxLysNM020e0Od5qJlYE0xeAt3s6kGHqrqQdwYNktulWZwYyWu8yO_ipJ5aZLi09fJHRbHOgXh4-dmhyxITPPY6j-0slUwmLc3BoW6uHYEq85XJYiN-cB8Dr9gbnq53B5saadr9IDct2Cg7w30H5I1VWySuwObD7JJdk-M8vpyj46aQsL5Ht2lJ40m-_IR-dGmCi1z2qIKbaiC3wBVqKUKBarQFapQTRWKVKGGKnRc0IoqFKlCa6rQiirvaEMUWhMFH2aJQltEoRXAqCYK1UShmiiPyflBf9Q7dGwHE0f4YbBwctn1OJhJ3GtX-57yJEQPWebLLOGsK8FZDpIcAiAvEqIbKQaLYSBzIaKukkGcZ_4TslGUhXpGqJQJz7IwkoJnQb6f8yBU4K13JVNxHItgi7jV1KbCyvtjl5lJimE-wz3r3hCbzrIU-84yuOBNfcHM_Kq3n_qqwko6n_LJBDDB0jZIt8jOCoSaO_qRH4FDDLeoMJXCAoa7krxQ5fU8BWiDI5HAQ54aqDXXWtRu__Hxz8m9xli8IBuLq2v1EoKFRbajWfMT9zgZHg
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Implications+of+Microscopic+Satellites+of+the+Primary+and+Extracapsular+Lymph+Node+Spread+in+Patients+With+High-Risk+Melanoma%3A+Pathologic+Corollary+of+Eastern+Cooperative+Oncology+Group+Trial+E1690&rft.jtitle=Journal+of+clinical+oncology&rft.au=U.N.M.+Rao&rft.au=J.+Ibrahim&rft.au=L.E.+Flaherty&rft.au=J.+Richards&rft.date=2002-04-15&rft.pub=American+Society+of+Clinical+Oncology&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=20&rft.issue=8&rft.spage=2053&rft_id=info:doi/10.1200%2FJCO.2002.08.024&rft_id=info%3Apmid%2F11956265&rft.externalDBID=n%2Fa&rft.externalDocID=jco20_8_2053
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon